flutamide has been researched along with Hemorrhagic Shock in 9 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Immediately after the completion of resuscitation, as well as 24 and 48 h thereafter, the animals received either vehicle, 10 mg/kg body weight (BW) flutamide or 25 mg/kg BW flutamide subcutaneously." | 7.69 | Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. ( Angele, MK; Ayala, A; Chaudry, IH; Cioffi, WG; Wichmann, MW, 1997) |
| "Flutamide failed to show any benefit to resuscitation in a model of severe injury and was associated with increased acidosis, hemodilution, and liver injury compared with standard crystalloid resuscitation." | 3.79 | Flutamide fails to reduce resuscitation requirements in a porcine ischemia-reperfusion model. ( Hempel, J; Hoffer, Z; Martin, M; Satterly, SA; Stallings, JD; Wingerd, M, 2013) |
| "Castrated and flutamide-treated male rats were significantly protected against trauma hemorrhagic shock (T/HS)-induced gut injury when compared with hormonally intact males." | 3.77 | Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymph. ( Deitch, EA; Feketeova, E; Lu, Q; Palange, D; Qin, X; Reino, DC; Sheth, SU; Wei, D; Xu, DZ, 2011) |
| "Flutamide, a testosterone receptor antagonist, produces various beneficial effects in male rats following hemorrhagic shock, possibly as a result of a direct vasodilating effect on large and small vessels in the rat." | 3.71 | Flutamide induces relaxation in large and small blood vessels. ( Ba, ZF; Bland, KI; Chaudry, IH; Kuebler, JF; Rue, LW; Wang, P, 2002) |
| " Immediately after the completion of resuscitation, as well as 24 and 48 h thereafter, the animals received either vehicle, 10 mg/kg body weight (BW) flutamide or 25 mg/kg BW flutamide subcutaneously." | 3.69 | Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock. ( Angele, MK; Ayala, A; Chaudry, IH; Cioffi, WG; Wichmann, MW, 1997) |
| "Flutamide appears to be a useful adjunct for improving vascular endothelial function and regional hemodynamics after trauma-hemorrhage and resuscitation." | 1.31 | Attenuation of vascular endothelial dysfunction by testosterone receptor blockade after trauma and hemorrhagic shock. ( Ba, ZF; Bland, KI; Chaudry, IH; Koo, DJ; Ornan, DA; Wang, P, 2001) |
| "Thus flutamide appears to be a novel and useful adjunct for improving cardiovascular and hepatocellular functions in males following trauma and hemorrhagic shock." | 1.30 | Testosterone receptor blockade after trauma-hemorrhage improves cardiac and hepatic functions in males. ( Bland, KI; Chaudry, IH; Cioffi, WG; Remmers, DE; Wang, P, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Satterly, SA | 1 |
| Martin, M | 1 |
| Wingerd, M | 1 |
| Hempel, J | 1 |
| Hoffer, Z | 1 |
| Stallings, JD | 1 |
| Sheth, SU | 1 |
| Palange, D | 1 |
| Xu, DZ | 1 |
| Wei, D | 1 |
| Feketeova, E | 1 |
| Lu, Q | 1 |
| Reino, DC | 1 |
| Qin, X | 1 |
| Deitch, EA | 1 |
| Ba, ZF | 2 |
| Wang, P | 3 |
| Kuebler, JF | 1 |
| Rue, LW | 1 |
| Bland, KI | 5 |
| Chaudry, IH | 7 |
| Yu, HP | 2 |
| Yang, S | 1 |
| Choudhry, MA | 3 |
| Hsieh, YC | 2 |
| Hildebrand, F | 1 |
| Thobe, BM | 1 |
| Hubbard, WJ | 1 |
| Pape, HC | 1 |
| Shimizu, T | 1 |
| Suzuki, T | 1 |
| Wichmann, MW | 1 |
| Angele, MK | 1 |
| Ayala, A | 1 |
| Cioffi, WG | 2 |
| Remmers, DE | 1 |
| Koo, DJ | 1 |
| Ornan, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men[NCT01686828] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We examined whether differences in lipoprotein lipase expression would be evident across study treatment groups. RNA was isolated from whole adipose tissue gene expression, and complementary DNA (cDNA) was synthesized from 1.5 ug of RNA per sample. Gene expression was measured by polymerase chain reaction (PCR) using predesigned TaqMan® Gene Expression Assays. Standard curves were included on each plate, so Ct values were converted to copy numbers of the target gene. Expression values were normalized to the geometric mean of the housekeeping genes phosphoglycerate kinase and 18s. (NCT01686828)
Timeframe: 4 weeks
| Intervention | gene copy number per ng RNA (Mean) |
|---|---|
| Acyline + Placebo Gel + Placebo Pills | 7493 |
| Acyline + Testosterone Gel (1.25g/d) + Placebo Pills | 8224 |
| Acyline + Testosterone Gel (5g/d) + Placebo Pills | 7885 |
| Acyline + Testosterone Gel (5g/d) + Letrozole | 8320 |
Whole body insulin sensitivity as quantified by Matsuda Index at the end of the treatment period, calculated by the following equation: 10,000/square root of(FPG*FI)*(FPG+PG30*2+PG60*2+PG90*2+PG120)/8*(FPI+PI30*2+PI60*2+PI90*2+PI)/8). FPG=fasting plasma glucose level; FPI=fasting plasma insulin level; PG30,60,90, and 120=plasma glucose levels sampled at 30,60,90, and 120 minutes after oral glucose load; PI30,60,90, and 120=plasma insulin levels sampled at 30,60,90, and 120 minutes after the oral glucose load (NCT01686828)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Acyline & Placebo Gel & Placebo Pill | 5.0 |
| Acyline & Testosterone Gel 1.25g/d & Placebo Pill | 9.4 |
| Acyline & Testosterone Gel 5g/d & Placebo Pill | 7.2 |
| Acyline & Testosterone Gel & Letrozole | 7.3 |
Fat mass and lean mass were measured by dual energy X-ray absorptiometry (DEXA) at baseline and at the end of the 4 week treatment period (NCT01686828)
Timeframe: 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Change in fat mass | Change in lean mass | |
| Acyline & Placebo Gel & Placebo Pill | 1.1 | -1.2 |
| Acyline & Testosterone Gel & Letrozole | 0.5 | -0.3 |
| Acyline & Testosterone Gel 1.25g/d & Placebo Pill | 0.7 | -1.4 |
| Acyline & Testosterone Gel 5g/d & Placebo Pill | -0.4 | 0.0 |
9 other studies available for flutamide and Hemorrhagic Shock
| Article | Year |
|---|---|
Flutamide fails to reduce resuscitation requirements in a porcine ischemia-reperfusion model.
Topics: Acidosis; Androgen Antagonists; Animals; Crystalloid Solutions; Cyclodextrins; Disease Models, Anima | 2013 |
Testosterone depletion or blockade in male rats protects against trauma hemorrhagic shock-induced distant organ injury by limiting gut injury and subsequent production of biologically active mesenteric lymph.
Topics: Animals; Castration; Disease Models, Animal; Flutamide; Gastrointestinal Tract; Lung Injury; Lymph; | 2011 |
Flutamide induces relaxation in large and small blood vessels.
Topics: Androgen Antagonists; Animals; Aorta, Thoracic; Dose-Response Relationship, Drug; Endothelium, Vascu | 2002 |
Mechanism responsible for the salutary effects of flutamide on cardiac performance after trauma-hemorrhagic shock: Upregulation of cardiomyocyte estrogen receptors.
Topics: Androgen Antagonists; Animals; Blood Pressure; Estrogen Receptor alpha; Estrogen Receptor beta; Flut | 2005 |
Effects of 17beta-estradiol and flutamide on splenic macrophages and splenocytes after trauma-hemorrhage.
Topics: Animals; CD3 Complex; Concanavalin A; Drug Synergism; Estradiol; Female; Flutamide; Interferon-gamma | 2006 |
Flutamide attenuates pro-inflammatory cytokine production and hepatic injury following trauma-hemorrhage via estrogen receptor-related pathway.
Topics: Abdominal Injuries; Androgen Antagonists; Animals; Chemokine CXCL1; Chemokines, CXC; Disease Models, | 2007 |
Flutamide: a novel agent for restoring the depressed cell-mediated immunity following soft-tissue trauma and hemorrhagic shock.
Topics: Animals; Body Weight; Corticosterone; Flutamide; Immunity, Cellular; Injections, Subcutaneous; Inter | 1997 |
Testosterone receptor blockade after trauma-hemorrhage improves cardiac and hepatic functions in males.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Animals; Blood Pressure; Cardiac Output; Flutam | 1997 |
Attenuation of vascular endothelial dysfunction by testosterone receptor blockade after trauma and hemorrhagic shock.
Topics: Acetylcholine; Androgen Antagonists; Androgen Receptor Antagonists; Animals; Aorta; Dose-Response Re | 2001 |